Startup profile · funding coverage
Acclinate funding, valuation and investors
Digital health equity platform using NOWINCLUDED community engagement and AI to improve clinical trial diversity.
Verified company research · funding, investors and latest developments
Keep track of Acclinate
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$7M · May 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$7M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Birmingham, AL
Investors in latest funding
Lead: Cencora Ventures
Other: Labcorp , Latimer Ventures
Overview
Acclinate helps life-sciences sponsors recruit and retain more representative clinical trial participants. Co-founded in 2020 by Del Smith and Tiffany Whitlow, the company combines its NOWINCLUDED community platform — culturally relevant health education and research opportunities for underrepresented populations — with AI/ML tools (including its e-DICT platform) that help sponsors plan and run more inclusive studies.
Headquartered in Birmingham, AL, Acclinate closed a $7M Series A in May 2024 led by Cencora Ventures, with Labcorp and Latimer Ventures participating. Earlier investors include Birmingham-based 450 Ventures.
Why Acclinate is interesting
FDA and pharma pressure on trial diversity created a commercial market Acclinate attacks with a community product (NOWINCLUDED) plus AI recruitment tech — not another patient-finder agency. Birmingham HQ; Series A led by a drug-distribution giant’s venture arm.
Product & use cases
Acclinate sells sponsors access to engaged communities via NOWINCLUDED and AI-assisted tools that surface representative cohorts, reduce recruitment friction, and support more inclusive protocol planning.
- Pharma and biotech sponsors improving racial and ethnic representation in trials
- CROs and sites needing community-trusted outreach beyond traditional recruitment vendors
- Sponsors planning future studies with predictive diversity insights
Key facts
- Series A (May 2024): $7M led by Cencora Ventures; Labcorp and Latimer Ventures participated
- NOWINCLUDED community platform plus e-DICT AI for clinical trial diversity
- HQ Birmingham, AL; founded 2020 by Del Smith and Tiffany Whitlow
- Seed backing includes Birmingham corporate VC 450 Ventures
Funding history (newest first)
Series A
2024-05 $7M- Cencora Ventures (lead)
- Labcorp (participant)
- Latimer Ventures (participant)
Source: Read source · prnewswire.com
Investors in our directory
Funds linked from Acclinate's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Pairs always-on community trust (NOWINCLUDED) with AI recruitment analytics — harder for pure staffing/recruitment shops to copy than a database alone.
-
Traditional patient recruitment agencies incumbent
Often transactional enrollment; less community ownership.
-
Trial matching marketplaces adjacent
Match patients to trials; may lack deep community engagement layer.
Industries
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Acclinate
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.